Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.


Results 1-4 of 4 (Search time: 0.001 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
2009Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueHochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T.
2014Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBaccarani, M.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Mongay, L.; Mone, M.; Ortmann, C.; Kantarjian, H.; Radich, J.; Hughes, T.; Cortes, J.; Guilhot, F.
2010Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity StudyCortes, A.; Baccarani, M.; Guilhot, F.; Druker, B.; Branford, S.; Kim, D.; Pane, F.; Pasquini, R.; Goldberg, S.; Kalaycio, M.; Moiraghi, B.; Rowe, J.; Tothova, E.; de Souza, C.; Rudoltz, M.; Yu, R.; Krahnke, T.; Kantarjian, H.; Radich, J.; Hughes, T.